GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Total Debt per Share

UPB (Upstream Bio) Total Debt per Share : $0.03 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Total Debt per Share?

$0.03 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Upstream Bio's Total Debt Per Share for the quarter that ended in Dec. 2024 was $0.03.


Upstream Bio Total Debt per Share Historical Data

The historical data trend for Upstream Bio's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Total Debt per Share Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24
Total Debt per Share
- - 0.03

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Total Debt per Share Get a 7-Day Free Trial - - - 0.04 0.03

Upstream Bio Total Debt per Share Calculation

Upstream Bio's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Upstream Bio's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Upstream Bio Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Upstream Bio Business Description

Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.